secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001193125-24-105037
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio closes $70M private placement to fund Phase 1/2 trial of KRRO-110
---------------------------------------------------------------------------

- Sold 1,249,283 shares at $56.00 per share for gross proceeds of ~$70M.
- Led by Deep Track Capital; includes Atlas Venture, Blue Owl, NEA, Rock Springs, Tri Locum.
- Proceeds plus existing $166.4M cash to fund Phase 1/2 trial of KRRO-110 in AATD through 2026.
- Piper Sandler, RBC Capital, BMO Capital Markets acted as placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312524105037/0001193125-24-105037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312524105037/d814636d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-105037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer